Roche raises guidance even after weak dollar weighs on sales

Group 1 - Roche has raised its full-year profit guidance, projecting adjusted earnings per share growth in the "high single to low double-digit" percentage range, up from a previous "high single-digit" percentage forecast [1][2] - The company confirmed its outlook for mid single-digit sales growth despite nine-month sales being impacted by foreign exchange effects, with revenues for the January-to-September period reported at 45.9 billion Swiss francs ($57.87 billion), below analyst forecasts of 46.2-46.4 billion francs [1][2] - CEO Thomas Schinecker's strategy includes significant investments in obesity drugs to compete with leading manufacturers Novo Nordisk and Eli Lilly, which may benefit from the improved earnings outlook [2]